Session 42-Oral Abstracts
HIV Persistence, Latency, and Eradication
Thursday, 10 am-12 noon; Room 6AB
10:00 am      151 Treatment of Early HIV Infection Reduces Viral Reservoir to Levels Found in Elite Controllers
Maria Buzon*1,2, K Seiss2, A Stone2, F Pereyra2,3, E Rosenberg1, X Yu2, and M Lichterfeld1
1Massachusetts Gen Hosp, Boston, US; 2Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US; and 3Brigham and Women`s Hosp, Boston, MA, US
10:15 am      152 Immediate Antiviral Therapy Restricts Resting CD4+ Infection but Does Not Accelerate the Decay of Latent Infection
N Archin1, N Vaidya2, J Kuruc1, C Gay1, M Kearney3, M Cohen1, J Coffin3, J Eron1, D Margolis1, and Alan Perelson*2
1Univ of North Carolina at Chapel Hill, US; 2Los Alamos Natl Lab, NM, US; and 3HIV Drug Resistance Prgm, NCI-Frederick, MD, US
10:30 am      153 Elimination of the Latent Reservoir for HIV-1 Requires Induction of Cytolytic T Lymphocyte Responses
Liang Shan*, K Deng, C Durand, A Rabi, J Blankson, and R Siliciano
Johns Hopkins Univ, Baltimore, MD, US
10:45 am      154 Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for AIDS-related Lymphoma
Anthony Cillo*1, A Krishnan2, R Mitsuyasu3, D McMahon1, S Li2, J Rossi2, J Zaia2, and J Mellors1
1Univ of Pittsburgh, PA, US; 2City of Hope Natl Med Ctr, Duarte, CA, US; and 3Univ of California, Los Angeles, US
11:00 am      155 Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV-infected Subjects
C June1, Pablo Tebas*1, D Stein2, R Mitsuyasu3, J Lalezari4, S Wang5, G Lee5, B Levine1, W Tang5, and D Ando5
1Univ of Pennsylvania, Philadelphia, US; 2Albert Einstein Coll of Med, Bronx, NY, US; 3Univ of California, Los Angeles, US; 4Quest Clin Res, San Francisco, CA, US; and 5Sangamo BioSci, Richmond, CA, US
11:15 am      156 Novel Structurally Related Compounds Reactivate Latent HIV-1 in a Bcl-2 Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation
Sifei Xing*1, S Bhat1, H Zhang2, J Lopez2, J Margolick2, J Liu1, and R Siliciano1,3
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Johns Hopkins Univ Sch of Publ Hlth, Baltimore, MD, US; and 3Howard Hughes Med Inst, Baltimore, MD, US
11:30 am  157LB Administration of Vorinostat Disrupts HIV-1 Latency in Patients on ART
N Archin1, A Liberty1, A Kashuba1, S Choudhary1, J Kuruc1, M Hudgens1, M Kearney2, J Eron1, D Hazuda3, and David Margolis*1
1Univ of North Carolina at Chapel Hill, US; 2HIV Drug Resistance Prgm, NCI-Frederick, MD, US; and 3Merck Res Labs, West Point, PA, US
11:45 am  158LB Effect of PD-1 Blockade following ART Interruption in SIV-infected Macaques
Vijayakumar Velu*1, K Titanji1, R Dyavar Shetty1, HW Lee1, G Freeman2, R Ahmed1, and R Amara1
1Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Emory Univ Sch of Med, Atlanta, GA, US and 2Harvard Med Sch, Boston, MA, US